// App-Quantinova.ai

: Why do clinicians withhold anticoagulation in patients with atrial fibrillation and CHA2DS2VASc score of 2 or higher?

Researchers

Presenter

  • D M Siegal

Principal Investigators

  • F Verbrugge

  • A C Martin

  • A Fiarresga

  • J Camm

  • K Pieper

  • K A A Fox

  • J P Bassand

  • S Haas

  • S Z Goldhaber

Medical Centers

  • McMaster University, Internal Medicine, Hamilton, Canada

  • University Hospitals (UZ) Leuven, Dept. of Cardiovascular Medicine, Leuven, Belgium

  • Hôpital d'Instruction des Armées Percy, Paris, France

  • Hospital de Santa Maria, Centro Hospital Lisboa Norte, Lisboa, Portugal

  • St George's, University of London, London, United Kingdom

  • Duke Clinical Research Institute - Durham - United States of America

  • University of Edinburgh, BHF/Centre for Cardiovascular Science, Edinburgh, United Kingdom

  • University of Besançon, Dept. of Cardiology, Besançon, France

  • Technical University Munich, 3rd Department of Medicine, Munich, Germany

  • Brigham and Women's Hospital - Boston - United States of America

Locations

  • Canada

  • Belgium

  • France

  • Portugal

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Multicenteric

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved